Related references
Note: Only part of the references are listed.Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives
Eunus S. Ali et al.
SEMINARS IN CANCER BIOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Management of patients with BRCA mutation from the point of view of a breast surgeon
M. L. Riis
ANNALS OF MEDICINE AND SURGERY (2021)
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane
Nazli Bahrami et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2020)
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Xuesai Zhang et al.
MOLECULAR IMMUNOLOGY (2020)
'Omics Approaches to Explore the Breast Cancer Landscape
Joseph Parsons et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Lin Shui et al.
FRONTIERS IN IMMUNOLOGY (2020)
Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents
Yasmine Alyassin et al.
DRUG DISCOVERY TODAY (2020)
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer
Yue Ming et al.
FRONTIERS IN ONCOLOGY (2020)
Novel targeted therapies for metastatic breast cancer
Khalid Jazieh et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Vikas Jain et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems
Patricia de Faria Lainetti et al.
PHARMACEUTICS (2020)
Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis
Zeeshan Ahmed
HUMAN GENOMICS (2020)
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Ajay Dhakal et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2020)
Breast Cancer Treatment
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Ivana Sestak et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides
Anabel Sorolla et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2019)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Manuel A. Ferreira et al.
NATURE COMMUNICATIONS (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
The applications of metabolomics in the molecular diagnostics of cancer
Pro Kit Cheung et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing
Lu Feng et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
Hira Choudhury et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
CDK4/6 inhibitors prolong OS
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Valentina Rossi et al.
CANCERS (2019)
Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries
Urania Dafni et al.
BREAST CARE (2019)
Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: A review
David Julian McClements
ADVANCES IN COLLOID AND INTERFACE SCIENCE (2018)
The challenge of drug resistance in cancer treatment: a current overview
Michail Nikolaou et al.
CLINICAL & EXPERIMENTAL METASTASIS (2018)
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer
Anne-Vibeke Laenkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
Lang Wu et al.
NATURE GENETICS (2018)
Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment
Katja Pinker et al.
RADIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Precision medicine in breast cancer
Yoichi Naito et al.
CHINESE CLINICAL ONCOLOGY (2018)
Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells
Yulia Malinovskaya et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Dynamic strategy for personalized medicine: An application to metastatic breast cancer
Xi Chen et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2017)
Molecular signatures in breast cancer
Samir Lal et al.
METHODS (2017)
Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics
Darrell D. Marshall et al.
PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (2017)
Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer
Guimin Gao et al.
PLOS GENETICS (2017)
Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk
Joshua D. Hoffman et al.
PLOS GENETICS (2017)
Awareness and current knowledge of breast cancer
Muhammad Akram et al.
BIOLOGICAL RESEARCH (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
Nutritional metabolomics and breast cancer risk in a prospective study
Mary C. Playdon et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2017)
Integrating Gene Expression with Summary Association Statistics to Identify Genes Associated with 30 Complex Traits
Nicholas Mancuso et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer
Yueling Yuan et al.
DRUG DELIVERY (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations
Abdellah Tebani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
Filip Janku et al.
CANCER RESEARCH (2015)
Nanoparticle therapeutics: Technologies and methods for overcoming cancer
Brenda Brenner S. Cerqueira et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Devon A. Lawson et al.
NATURE (2015)
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Kyriaki Michailidou et al.
NATURE GENETICS (2015)
Precision medicine for metastatic breast cancer-limitations and solutions
Monica Arnedos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Clinical proteomics and breast cancer
Bashar A. Zeidan et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2015)
Functional metabolomics: from biomarker discovery to metabolome reprogramming
Bo Peng et al.
PROTEIN & CELL (2015)
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Peter Eirew et al.
NATURE (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way
Nuket Eliyatkin et al.
JOURNAL OF BREAST HEALTH (2015)
Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC
Sibylle Loibl et al.
CURRENT BREAST CANCER REPORTS (2015)
Electrochemotherapy: from the drawing board into medical practice
Damijan Miklavcic et al.
BIOMEDICAL ENGINEERING ONLINE (2014)
Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents
Yuxia Cui et al.
CELL CYCLE (2014)
Personalized medicine: Present and future of breast cancer management
Renaud Sabatier et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre
Terri Patricia McVeigh et al.
EUROPEAN JOURNAL OF CANCER (2014)
Breast cancer patient stratification using a molecular regularized consensus clustering method
Chao Wang et al.
METHODS (2014)
The potential legacy of cancer nanotechnology: celluar selection
Hirak K. Patra et al.
TRENDS IN BIOTECHNOLOGY (2014)
Serum Soluble CD14 Is a Potential Prognostic Indicator of Recurrence of Human Breast Invasive Ductal Carcinoma with Her2-Enriched Subtype
Weifeng He et al.
PLOS ONE (2013)
Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model
Caroline H. Johnson et al.
METABOLITES (2013)
Recent trends in cancer drug resistance reversal strategies using nanoparticles
Srinath Palakurthi et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Dietary Intake of Specific Fatty Acids and Breast Cancer Risk Among Postmenopausal Women in the VITAL Cohort
Anna K. Sczaniecka et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2012)
Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease
Xu-Hua Xu et al.
NEUROSCIENCE BULLETIN (2012)
Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
P-L Jerevall et al.
BRITISH JOURNAL OF CANCER (2011)
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles
Chunbai He et al.
BIOMATERIALS (2010)
Combinatorial biomarker expression in breast cancer
Emad A. Rakha et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Breast Cancer in the Personal Genomics Era
Rachel E. Ellsworth et al.
CURRENT GENOMICS (2010)
Breast cancer genomes - form and function
James Korkola et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
The role of HER2 in cancer therapy and targeted drug delivery
Wanyi Tai et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer
Monika Pietrowska et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
Nasim Ahmadiyeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
Edith A. Perez
BREAST CANCER RESEARCH AND TREATMENT (2009)
Identification of Differentially Expressed Proteins in Triple-Negative Breast Carcinomas Using DIGE and Mass Spectrometry
Daniela M. Schulz et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS
Melinda E. Sanders et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Common and rare variants in multifactorial susceptibility to common diseases
Walter Bodmer et al.
NATURE GENETICS (2008)
The molecular pathology of hereditary breast cancer
J. Palacios et al.
PATHOBIOLOGY (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer
Claudio Belluco et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer
Y. S. Chin et al.
BREAST (2007)
Differential signal transduction of alternatively spliced FGFR2 variants expressed epithelial in human mammary cells
Allison B. Moffa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients
Paolo Carlini et al.
CANCER INVESTIGATION (2007)
Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues
Jane Key et al.
CANCER CAUSES & CONTROL (2006)
Proteomic analysis in human breast cancer: Identification of a characteristic protein expression profile of malignant breast epithelium
G Hudelist et al.
PROTEOMICS (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
JV Moyano et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry
JN Li et al.
CLINICAL CHEMISTRY (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility:: Systematic evidence review for the US Preventive Services Task Force
HD Nelson et al.
ANNALS OF INTERNAL MEDICINE (2005)
Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry
A Umar et al.
PROTEOMICS (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Chemosensitivity prediction by transcriptional profiling
JE Staunton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
A gene expression database for the molecular pharmacology of cancer
U Scherf et al.
NATURE GENETICS (2000)
Share Paper
